Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024GlobeNewsWire • 06/12/24
Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/31/24
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™GlobeNewsWire • 05/29/24
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 05/16/24
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate UpdateGlobeNewsWire • 05/13/24
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing SymposiumGlobeNewsWire • 04/17/24
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual MeetingGlobeNewsWire • 04/08/24
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual ConferencesGlobeNewsWire • 04/01/24
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate UpdateGlobeNewsWire • 03/21/24
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care ConferenceGlobeNewsWire • 02/29/24
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded WarrantsGlobeNewsWire • 02/29/24
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsGlobeNewsWire • 02/28/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MISTPRNewsWire • 01/23/24
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a TurnaroundZacks Investment Research • 01/16/24
ROSEN, A LEADING AND RANKED FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - MISTPRNewsWire • 01/07/24
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)Benzinga • 01/02/24
ROSEN, A LONGSTANDING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - MISTPRNewsWire • 12/30/23
ROSEN, A LEADING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MISTBusiness Wire • 12/26/23
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVTGlobeNewsWire • 12/26/23
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferencePRNewsWire • 11/21/23
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatesPRNewsWire • 11/13/23
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023PRNewsWire • 11/11/23
Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVRPRNewsWire • 11/07/23